David Berry | |
|---|---|
 Berry in 2015 | |
| Born | February 10, 1978 |
| Education | MIT, Harvard Medical School |
| Occupation(s) | CEO, innovator, venture capitalist, entrepreneur, inventor, |
David Berry (born February 10, 1978) is an American entrepreneur and business executive. He has co-founded Valo Health, Seres Therapeutics, Indigo Agriculture, Axcella Health, and contributed to the early development of Moderna. [1]
Berry was born in 1978. He graduated Hackley School in Tarrytown, NY in 1996. Berry graduated with a S.B. Phi Beta Kappa and Sigma Xi from the Massachusetts Institute of Technology in 2000. He earned his M.D. from Harvard Medical School and his PhD from the Massachusetts Institute of Technology with Robert Langer and Ram Sasisekharan.[ citation needed ]
Berry joined Flagship Pioneering in 2005, a Cambridge, Massachusetts based venture capital firm that funds early-stage start-ups in healthcare and sustainability, where he served as a general partner. [2]
In 2007, Berry founded Joule Unlimited.
In 2009, Berry founded Axcella Health, which develops a new approach to treating complex diseases using Endogenous Metabolic Modulators (EMMs) as a new therapeutic product class. [3]
In March 2010, [4] and again in March 2011, Joule Unlimited was named by Technology Review as one of the 50 Most Innovative Companies. [5]
In 2012, Berry founded Seres Therapeutics, which pioneered microbiome therapeutics. [6] The company raised over $130M as a private company, including a $65M investment from Nestle Health Sciences. [7] Seres publicly listed on the Nasdaq under the symbol MCRB in June 2015, raising $134M. [8] Seres signed a partnership valued at $2B with Nestle Health Sciences in early 2016. [9]
In 2014, Berry founded Indigo Agriculture to create seed treatments that optimize the health of a plant to increase yield. [10] The same year, Berry founded Evelo Biosciences. [11]
Berry founded Valo Health in 2019. [12] [13]
Berry is a founding member of the Leadership Council of the United Nations Sustainable Development Solutions Network, which authored the Sustainable Development Goals. [14]
He was named as the Innovator of the Year in 2007 by the MIT Technology Review TR35 list for his creation of LS9. [15] Berry was selected as a 2014 Young Global Leader by the World Economic Forum. [16] Additionally Berry has been recognized by the US State Department as one of 12 Innovators Helping Reshape Reality. [17]
Berry is a trustee at the Hackley School, [18] and was previously a board member of the Massachusetts Institute of Technology from 2006-2011. [19] David has also served as a board member of the Juventas New Music Ensemble [20] and of the Boston Philharmonic Orchestra.
Robert Samuel Langer Jr. FREng is an American biotechnologist, businessman, chemical engineer, chemist, and inventor. He is one of the twelve Institute Professors at the Massachusetts Institute of Technology.
The Innovators Under 35 is a peer-reviewed annual award and listicle published by MIT Technology Review magazine, naming the world's top 35 innovators under the age of 35.
John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.
Erez Lieberman Aiden is an American research scientist active in multiple fields related to applied mathematics. He is an associate professor at the Baylor College of Medicine, and formerly a fellow at the Harvard Society of Fellows and visiting faculty member at Google. He is an adjunct assistant professor of computer science at Rice University. Using mathematical and computational approaches, he has studied evolution in a range of contexts, including that of networks through evolutionary graph theory and languages in the field of culturomics. He has published scientific articles in a variety of disciplines.
Joule Unlimited, formerly known as Joule Biotechnologies, was a producer of alternative energy technologies based in Bedford, Massachusetts. The company developed a process to generate hydrocarbon-based fuel by combining non-fresh water, nutrients, cyanobacteria, carbon dioxide, and sunlight. After ten years of operation and building a demonstration plant in New Mexico, the company shut down in August 2017. The company shut down after management was unable to raise money.
Nathaniel David is an American scientist and entrepreneur who co-founded a series of technology companies in the biotechnology and sustainable energy sectors, including Syrrx, Achaogen, Kythera Biopharmaceuticals, Sapphire Energy and Unity Biotechnology. These companies have collectively raised more than $1.5 billion in financing.
Daphne Zohar is an American entrepreneur. She is the founder and CEO of PureTech Health, a biotechnology firm. PureTech went public in June 2015 and is a FTSE250 company.
Chris Rivest is an American entrepreneur and co-founder of SunPrint, a company that develops technology to inexpensively fabricate solar cells using acoustic printing. He is a graduate of the Massachusetts Institute of Technology.
Jeffrey Karp is a Canadian biomedical engineer working as a Professor of Medicine at Harvard Medical School, Brigham and Women's Hospital, and the principal faculty at the Harvard Stem Cell Institute and Affiliate Faculty at the Massachusetts Institute of Technology through the Harvard–MIT Division of Health Sciences and Technology. He is also an affiliate faculty at the Broad Institute.
Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health, Generate Biomedicines and Tessera Therapeutics. He has over 200 bioengineering and biotechnology patents and applications.
uBiome, Inc. was a biotechnology company based in San Francisco that developed technology to sequence the human microbiome. Founded in 2012, the company filed for bankruptcy in 2019 following an FBI raid in an investigation over possible insurance fraud involving the US health insurance program Medicare.
Ryan Bethencourt is an American scientist, entrepreneur, and biohacker best known for his work as co-founder and CEO of Wild Earth, Partner at Babel Ventures and cofounder and former Program Director at IndieBio, a biology accelerator and early stage seed fund. Bethencourt was head of life sciences at the XPRIZE foundation, a co-founder and CEO of Berkeley Biolabs, a biotech accelerator, and Halpin Neurosciences, an ALS therapeutics-focused biotech company. Bethencourt co-founded Counter Culture Labs, a citizen science nonprofit, and Sudo Room, a hacker space based in downtown Oakland, California.
Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.
Kay M. Tye is an American neuroscientist and professor and Wylie Vale Chair in the Salk Institute for Biological Sciences. Her research has focused on using optogenetics to identify connections in the brain that are involved in innate emotion, motivation and social behaviors.
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
David Perry was the CEO and Director of Indigo Agriculture, an agricultural technology company headquartered in Boston, United States. He is a serial entrepreneur in the life sciences industry. He has co-founded Anacor Pharmaceuticals, Chemdex, NexPrise, Virogen and FareWell.
Emily P. Balskus is an American chemical biologist, enzymologist, microbiologist, and biochemist born in Cincinnati, Ohio in 1980. She has been on the faculty of the Chemistry and Chemical Biology department of Harvard University since 2011 and is currently the Morris Kahn Professor. She has published more than 80 peer-reviewed papers and three book chapters. Since 2012 she has been invited to give over 170 lectures, has held positions on various editorial boards, and served as a reviewer for ACS and Nature journals among others. Balskus also currently serves as a consultant for Novartis, Kintai Therapeutics, and Merck & Co.
Flagship Pioneering is an American life sciences venture capital company based in Cambridge, Massachusetts that invests in biotechnology, life sciences, health and sustainability companies. Portfolio companies include Moderna, Indigo Agriculture, Inari Agriculture and Novomer. The firm both funds and incubates companies.
The Wyss Institute for Biologically Inspired Engineering is a cross-disciplinary research institute at Harvard University focused on bridging the gap between academia and industry by drawing inspiration from nature's design principles to solve challenges in health care and the environment. It is focused on the field of biologically inspired engineering to be distinct from bioengineering and biomedical engineering. The institute also has a focus on applications, intellectual property generation, and commercialization. The Wyss Institute is located in Boston's Longwood Medical Area and has 375 full-time staff. The Wyss is organized around eight focus areas, each of which integrate faculty, postdocs, fellows, and staff scientists. The focus areas are bioinspired therapeutics & diagnostics, diagnostics accelerator, immuno-materials, living cellular devices, molecular robotics, 3D organ engineering, predictive bioanalytics and synthetic biology.